Wei et al., 2013 - Google Patents
Design, synthesis and biological evaluation of enzymatically cleavable NSAIDs prodrugs derived from self-immolative dendritic scaffolds for the treatment of …Wei et al., 2013
- Document ID
- 1540612645569734667
- Author
- Wei J
- Shi J
- Zhang J
- He G
- Pan J
- He J
- Zhou R
- Guo L
- Ouyang L
- Publication year
- Publication venue
- Bioorganic & Medicinal Chemistry
External Links
Snippet
It has been reported that delivery systems based on dendritic prodrugs of Nonsteroidal Anti- Inflammatory Drugs (NSAIDs) improved the properties of drug molecules and reduced the side effects and irritation on the gastric mucosa. To find a more effective way in NSAIDs …
- 239000000651 prodrug 0 title abstract description 52
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
- A61K47/48023—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound
- A61K47/48061—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound the modifying agent being a heterocyclic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
- A61K47/48023—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound
- A61K47/481—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds, e.g. a polymer of aspirin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
- A61K47/48192—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule the organic macromolecular compound has been obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas, polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P-C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6949206B2 (en) | Method for producing antibody-drug conjugate intermediate | |
| US7812051B2 (en) | Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential | |
| Wei et al. | Design, synthesis and biological evaluation of enzymatically cleavable NSAIDs prodrugs derived from self-immolative dendritic scaffolds for the treatment of inflammatory diseases | |
| JP5349318B2 (en) | Steroids polymer conjugates | |
| Ouyang et al. | Selective bone targeting 5-fluorouracil prodrugs: synthesis and preliminary biological evaluation | |
| England et al. | Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers | |
| WO2007048190A1 (en) | Macromolecular compounds having controlled stoichiometry | |
| CN101787064B (en) | Cytarabine derivatives and purposes thereof in resisting cancers and tumors | |
| KR102440763B1 (en) | One-pot method for preparing intermediates of antibody-drug conjugates | |
| Markad et al. | A primary amide-functionalized heterogeneous catalyst for the synthesis of coumarin-3-carboxylic acids via a tandem reaction | |
| US20250195532A1 (en) | Novel phosphoinositide 3-kinase (pi3k) inhibitor, compositions comprising the same, methods of making, and methods of treating a disease | |
| JP4467888B2 (en) | Aloe-emodin derivatives and their use in the treatment of neoplastic pathology | |
| Gopin et al. | New chemical adaptor unit designed to release a drug from a tumor targeting device by enzymatic triggering | |
| EP2123305B1 (en) | Linear self-eliminating oligomers | |
| Zacchigna et al. | PEG–ursolic acid conjugate: Synthesis and in vitro release studies | |
| CN100588428C (en) | Fluorouracil-dextran conjugate and preparation method thereof | |
| CN110183504B (en) | A kind of gemcitabine prodrug with tumor targeting and its preparation method and application | |
| CN106083999A (en) | A kind of ibuprofen polypeptide coupling compound and aqueogel thereof | |
| CN107236055B (en) | A kind of glucan derivative and its application | |
| KR101971336B1 (en) | Target-specific anti-cancer prodrug and method for preparing the same | |
| CN114437151B (en) | Albumin-binding camptothecin derivative prodrug, and preparation method and application thereof | |
| Cogan et al. | Doxsaliform: A novel N-Mannich base prodrug of a doxorubicin formaldehyde conjugate | |
| CN115873066A (en) | Synthetic method of antibody-conjugated drug linker | |
| Huang et al. | Synthesis, Characteristics, and Pharmaceutical Properties of Ibuprofen‐Cyclodextrin‐PEG Conjugate | |
| US20100105857A1 (en) | Dendrimeric platform for controlled release of drugs |